Teva back on the hook for $235M to GSK for heart drug infringement

After a jury in 2017 ordered Teva to pay $235 million for patent infringement of a GlaxoSmithKline heart drug, the generics giant convinced a district judge to nix the verdict. But now, its fortunes have changed again.